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Differences in the Concentrations of Small, Anionic, Antimicrobial
Peptides in Bronchoalveolar Lavage Fluid and in Respiratory Epithelia of
Patients with and without Cystic Fibrosis
Abstract
Affinity-purified rabbit polyclonal (PAB96-1) and mouse monoclonal (1G9-1C2) antibodies to synthetic H-
DDDDDDD-OH, an antimicrobial anionic peptide (AP) originally isolated from ovine pulmonary
surfactant, were prepared and used to assess the concentrations of AP-like molecules in human respiratory
tract samples. In bronchoalveolar lavage fluids, concentrations of AP-like molecules measured by enzyme-
linked immunosorbent assay were significantly lower in 13 patients with cystic fibrosis (CF) (mean ± standard
deviation [SD], 0.78 ± 0.46 mM) than in 34 patients without CF (1.30 ± 0.66 mM) (P = 0.01). In pulmonary
tissues of three patients without CF, very little antigen was stained in the apical cytoplasm of the bronchial and
bronchiolar epithelium yet robust staining was seen in the alveolar epithelium. In pulmonary tissues of three
patients with CF, robust staining of antigen was seen in the apical cytoplasm of the bronchial and bronchiolar
epithelium yet no staining was seen in the alveolar epithelium. These results show that AP-like molecules are
present in healthy human respiratory tract samples and differ in concentration and location of expression in
patients with and without CF.
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Affinity-purified rabbit polyclonal (PAB96-1) and mouse monoclonal (1G9-1C2) antibodies to synthetic
H-DDDDDDD-OH, an antimicrobial anionic peptide (AP) originally isolated from ovine pulmonary surfac-
tant, were prepared and used to assess the concentrations of AP-like molecules in human respiratory tract
samples. In bronchoalveolar lavage fluids, concentrations of AP-like molecules measured by enzyme-linked
immunosorbent assay were significantly lower in 13 patients with cystic fibrosis (CF) (mean 6 standard
deviation [SD], 0.78 6 0.46 mM) than in 34 patients without CF (1.30 6 0.66 mM) (P 5 0.01). In pulmonary
tissues of three patients without CF, very little antigen was stained in the apical cytoplasm of the bronchial and
bronchiolar epithelium yet robust staining was seen in the alveolar epithelium. In pulmonary tissues of three
patients with CF, robust staining of antigen was seen in the apical cytoplasm of the bronchial and bronchiolar
epithelium yet no staining was seen in the alveolar epithelium. These results show that AP-like molecules are
present in healthy human respiratory tract samples and differ in concentration and location of expression in
patients with and without CF.
Patients with cystic fibrosis (CF) are predisposed to pulmo-
nary infections, and this predisposition contributes to much of
the morbidity and mortality associated with this highly preva-
lent inherited disease (6). One explanation for the increased
susceptibility of these individuals to infection is a breakdown in
local pulmonary innate immune mechanisms. For example,
Smith et al. (14) demonstrated a striking correlation between
the colonization of cultured airway epithelial cells in CF pa-
tients by Pseudomonas aeruginosa and a loss of endogenous
epithelial cell antimicrobial activity. Subsequently, both the
physiologic parameters leading to the loss of antimicrobial
activity of airway epithelial cells in CF patients (e.g., the de-
termination of NaCl concentration in airway lining fluid and its
effect on antimicrobial activity) and the identification of all
antimicrobial mechanisms in these tissues, cells, and secretions
came under intense investigation. Some of these antimicrobial
systems are just being defined (14), whereas others are known
to involve cationic human b-defensins (8, 13), antimicrobial frag-
ments of surfactant proteins (10), lysozyme (1), secretory leuko-
protease inhibitor (9, 15), lactoferrin (16), and cathelicidins (2).
Three small, antimicrobial anionic peptides (AP), H-GAD-
DDDD-OH, H-GDDDDDD-OH, and H-DDDDDDD-OH,
are also present in ovine surfactant extracts (5), bronchoalveo-
lar lavage (BAL) fluid, and airway epithelial cells (3). These
peptides occur in millimolar concentrations (3), require zinc as
a cofactor for antimicrobial activity (5), and are rapidly anti-
microbial against both gram-positive and gram-negative organ-
isms, including P. aeruginosa (4).
Since AP were detected in ovine BAL fluid by enzyme-
linked immunosorbent assay (ELISA) and in ovine pulmonary
epithelia by immunohistochemistry with affinity-purified poly-
clonal and monoclonal antibodies to H-DDDDDDD-OH (3),
we were interested in whether these antibodies detect AP-like
molecules in human BAL fluids and pulmonary epithelia. In
this study, we show that AP-like molecules are detected in
human BAL fluid and pulmonary epithelia and differ in con-
centration and location of expression in patients with and with-
out CF.
Native BAL fluid from 47 patients (13 patients with CF and
34 patients without CF) and formalin-fixed pulmonary tissues
from 6 patients (3 patients with CF and 3 patients without CF)
were collected as approved by the Institutional Review Board,
Department of Pediatrics, Allergy/Pulmonary Division, The
University of Iowa Hospitals and Clinics. CF-unrelated BAL
fluids were collected from healthy volunteers (n 5 23) and
patients with pulmonary infections (n 5 6), asthma (n 5 2),
genetic disorders (n 5 2), and alveolar proteinosis (n 5 1).
CF-unrelated pulmonary tissues (n 5 3) were collected from
patients who had died from nonpulmonary causes (i.e., head
injuries from car accidents). They had all been maintained on
ventilators transiently, and the lungs were deemed to be not
suitable for transplant. Pulmonary pathology, typical of that in
patients on ventilators, was present.
H-DDDDDDD-OH was synthesized by Multiple Peptide
Systems (San Diego, Calif.) by using Merrifield resins and
standard tert-butoxycarbonyl chemistry in combination with si-
multaneous multiple peptide synthesis as previously described
(3, 4). Peptide quality and composition were assessed by ana-
* Corresponding author. Mailing address: Respiratory and Neuro-
logic Disease Research Unit, National Animal Disease Center, Agri-
cultural Research Service, U.S. Department of Agriculture, P.O. Box
70, 2300 Dayton Rd., Ames, IA 50010. Phone: (515) 239-8593. Fax:
(515) 239-8458. E-mail: kbrogden@nadc.ars.usda.gov.
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lytical high-performance liquid chromatography, plasma de-
sorption mass spectral analysis performed on a Biolon 20 Mass
Analyzer, and amino acid analysis. Lyophilized peptide was 95
to 99% pure.
Affinity-purified rabbit polyclonal antibody (PAB96-1) and
mouse monoclonal antibody (1G9-1C2) to H-DDDDDDD-OH
were prepared, and their specificities and epitope binding sites
were characterized in a competitive ELISA and with a SPOTs
Epitope Mapping kit, respectively, as recently described (3).
Both antibodies were specific for AP with C-terminal Asp
residues (3). Epitopes that contained more than two C-termi-
nal Asp residues were recognized by antibody 1G9-1C2 (at a
concentration of 25 mg/ml only). Antibody PAB96-1, which was
affinity purified on a gel coupled with H-DDDDDDD-OH,
recognized only H-DDDDDDD-OH (at both 5- and 25-mg/ml
concentrations).
The concentration of AP-like molecules in BAL fluid was
assessed by direct ELISA performed as recently described (3)
with both antibodies (PAB96-1 and 1G9-1C2). Native BAL
fluid (100 ml) from each patient was incubated overnight at
26°C in high protein binding styrene plates (Immulon 4; Dynex
Technologies, Inc., Chantilly, Va.). The positive control was syn-
thetic peptide H-DDDDDDD-OH (1.0 to 0.063 mM) added to
surfactant (1.0 mg/ml) from sheep 3149 (5), and the negative
control was surfactant (1.0 mg/ml) from sheep 3149 without
peptide. After 16 h, wells were blocked with gelatin blocking
buffer. Either antibody PAB96-1 or antibody 1G9-1C2 (1.0 mg
of antibody per ml of blocking buffer) was added and incubated
for 1 h. The wells were washed, and bound antibody was
detected with either peroxidase-labeled goat anti-mouse im-
munoglobulin G (IgG) (human serum-absorbed IgG, 1.0 mg
per ml of blocking buffer) (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, Md.) or peroxidase-labeled goat anti-rabbit
IgG (1.0 mg per ml of blocking buffer; Kirkegaard & Perry
Laboratories, Inc.). Bound peroxidase-labeled antibody was
detected with tetramethylbenzidine (TMB substrate and stop
system; Kirkegaard & Perry Laboratories, Inc.). Concentrations
of AP-like molecules in the BAL fluids were determined after
extrapolation of their optical densities from those generated by a
standard curve of synthetic peptide H-DDDDDDD-OH diluted
within the range from 1.0 to 0.063 mM. Statistical differences
among groups were determined by a one-way analysis of variance
(SigmaStat 2.03; Jandel Scientific Corp., San Rafael, Calif.).
BAL fluid from patients with CF likely has additional pro-
tein that may compete with AP-like molecules for binding sites
in the ELISA plates and thus give the appearance of artificially
lower concentrations of AP-like molecules in these samples.
To demonstrate the validity of the ELISA for quantitation of
AP-like molecules, a representative set of BAL fluid samples
(three samples from patients with CF and three samples from
patients without CF) were diluted twofold. The ELISA was
performed as described above. In all samples, a linear relation-
ship was seen between the amount of protein in the BAL fluid
and the optical density of the ELISA reaction mixture
(mean 6 standard deviation [SD], correlation coefficient,
0.80 6 0.24). No significant differences were seen between the
correlation coefficients for the groups. This shows that addi-
tional protein that may occur in the BAL fluid sample from a
CF patient does not compete with AP-like molecules for bind-
ing sites in the ELISA plates or give the appearance of artificially
lower concentrations of AP-like molecules in these samples.
Pulmonary tissues (from three patients with CF and three
patients without CF) were sectioned onto ProbeOn Plus mi-
croscope slides (Fisher Scientific, Pittsburgh, Pa.) and pro-
cessed for immunocytochemical detection of AP-like mole-
cules. Briefly, paraffin was removed with xylene and the
sections were rehydrated in 100% ethanol–90% ethanol–70%
ethanol and rinsed in ultrapure water. The sections were then
incubated in a gelatin blocking buffer containing 50% normal
goat serum, washed in gelatin blocking buffer, washed again in
50% normal goat blocking serum, and incubated with antibody
1G9-1C2 (2.0 mg/ml) overnight at 4°C. Sections were then
washed in gelatin blocking buffer, incubated with biotinylated
goat anti-mouse antibody (Biogenex, San Ramon, Calif.),
washed in buffer, and incubated in streptavidin-alkaline phos-
phatase for 30 min at room temperature. The color was devel-
oped with New Fuchsin (Biogenex). Sections were then coun-
terstained with hematoxylin for 1 min (Shannon Lipshaw),
dehydrated, infiltrated, and mounted.
The immunohistochemical procedure was optimized after a
series of trials. Control tissue sections were processed as de-
scribed above but without antibody 1G9-1C2 or with antibody
1G9-1C2 preincubated with 0.5 mM H-DDDDDDD-OH. In
both of these controls, staining specific to H-DDDDDDD-OH
could not be detected. Tissue sections were also incubated with
trypsin for 15 or 30 min or heated in a microwave for 10 min
in either pH 6.0 citrate buffer (Biogenex) or Tris buffer (pH
10.0) to further expose H-DDDDDDD-OH in cells. None of
these treatments dramatically increased staining specific to
H-DDDDDDD-OH. Tissue sections were also incubated in a
variety of blocking buffer solutions, including those that con-
tained fish gelatin, 10, 50, and 100% normal goat serum, fish
gelatin with either 10, 50, and 100% normal goat serum, or a
commercial blocker (Powerblock; Biogenex). Gelatin blocking
buffer containing 50% normal goat serum was chosen and was
found to enhance specificity as well as reduce nonspecific back-
ground and nuclear staining.
AP-like molecules were detected with antibody 1G9-1C2,
and the concentrations were significantly lower in the 13 pa-
tients with CF (mean 6 SD, 0.78 6 0.46 mM) than in the 34
patients without CF (mean 6 SD, 1.30 6 0.66 mM) (P 5 0.01).
AP-like molecules were also detected with antibody PAB96-1,
and the concentrations were similar to those detected with 1G9-
1C2 and also significantly different between groups (P , 0.001).
Lesions were present in all six pulmonary tissues. Patients
without CF had mild suppurative bronchopneumonia, suppu-
rative bronchopneumonia, or bronchial ectasia with loss of
cilia. Patients with CF had multifocal chronic lymphocytic
bronchitis or severe diffuse chronic-active bronchopneumonia.
Immunohistochemical staining of pulmonary tissues with an-
tibody 1G9-1C2 differed between groups (Fig. 1). For patients
without CF, very little antigen was stained in the apical cyto-
plasm of the bronchial and bronchiolar epithelium (Fig. 1A)
yet robust staining was seen in the alveolar epithelium (these
findings were observed in all of three tissue sections; 60 to 90%
of cells in the alveolar epithelium were stained; Fig. 1B). A
similar pattern of nuclear staining was also seen: from 10 to
30% of bronchial and bronchiolar epithelial cell nuclei were
stained (Fig. 1A), and 60 to 90% of alveolar epithelial cell
nuclei were stained (Fig. 1B).
In patients with CF, moderate staining of antigen was seen
in the apical cytoplasm of the bronchial and bronchiolar epi-
thelium (Fig. 1C) yet no staining was seen in the alveolar
epithelium (these findings were observed in all of three tissue
sections; only 10 to 30% of alveolar epithelial cells were
stained; Fig. 1D). In addition, tissues from these patients had
peribronchial and peribronchiolar lymphocytic infiltrates con-
taining some stained lymphocytes. Neutrophils or suppurative
exudate did not stain. Again, a similar pattern of nuclear stain-
ing was seen. From 60 to 90% of bronchial and bronchiolar
epithelial cell nuclei were stained (Fig. 1C), and ,10% of
alveolar epithelial cell nuclei were stained (Fig. 1D).
VOL. 67, 1999 NOTES 4257
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Overall, AP-like molecules were detected in human BAL
fluid, demonstrating the presence of peptides with a composi-
tion similar to H-DDDDDDD-OH, an antimicrobial AP orig-
inally isolated from ovine pulmonary surfactant (3, 5). This was
not an unexpected finding as others have reported similar
results. In the 1980’s, antimicrobial AP-like molecules were
partially isolated from mouse, rabbit, and human BAL fluid
(11, 12). Biochemical characterization of the partially purified
extracts demonstrated that the antimicrobial activity was heat
stable and trypsin sensitive and that this activity was reversed
FIG. 1. Immunohistochemical staining of pulmonary tissues from patients without CF and patients with CF. (A) In patients without CF, antibody 1G9-1C2 to
H-DDDDDDD-OH stained very little antigen in the apical cytoplasm of the bronchial and bronchiolar epithelium and in the cytoplasm of pulmonary endothelial cells
and sporadic alveolar macrophages (in all of three tissues examined). From 10 to 30% of bronchial and bronchiolar epithelial cell nuclei were also stained. (B) In
patients without CF, robust cytoplasmic staining of alveolar type I epithelium was seen (in all of three tissue sections examined; 60 to 90% of cells were stained). From
60 to 90% of alveolar epithelial cell nuclei were also stained. (C) In patients with CF, moderate staining of antigen was seen in the apical cytoplasm of the bronchial
and bronchiolar epithelium (in all of three tissue sections examined; 60 to 90% of cells were stained). From 60 to 90% of bronchial and bronchiolar epithelial cell nuclei
were also stained. (D) In patients with CF, no cytoplasmic staining of alveolar type I epithelium was seen (in all of three tissue sections examined; only 10 to 30% of
the cells were stained). Less than 10% of alveolar epithelial cell nuclei were stained.
4258 NOTES INFECT. IMMUN.
 o
n
 February 25, 2013 by IO
W
A STATE UNIVERSITY
http://iai.asm
.org/
D
ow
nloaded from
 
by incubation with the cation chelator EDTA. A rough esti-
mate of peptide molecular size was 3.4 kDa. A similar mole-
cule was isolated from human BAL fluid (7). Reverse-phase
high-performance liquid chromatography fractionation led to
partial purification of an antibacterial peptide which behaved
as an anionic peptide with a molecular size of ,10 kDa and
whose activity was heat stable, Zn dependent, and inhibited by
both EDTA and phosphate.
The concentration of AP-like molecules was significantly
lower in patients with CF than in those without CF. This is an
interesting finding and suggests a physiologic deficiency in pep-
tide concentration which may predispose patients with CF to
respiratory infections. This finding is contrary to the situation
proposed for other antimicrobial substances that are present in
similar amounts in patients with and without CF yet are inac-
tivated in the increased NaCl content environment in the air-
way lining fluid of CF patients (14).
AP-like antigen was also detected in the respiratory epithelia
of patients with and without CF; this finding is similar to the
immunohistochemical results seen in sheep pulmonary tissues
(3). In that study, antibodies PAB96-1 and 1G9-1C2 identified
antigen in the apical cytoplasm of the bronchial and bronchio-
lar epithelia and in the cytoplasm of pulmonary endothelial
cells and sporadic alveolar macrophages (3). Goblet cells and
epithelial cells of pulmonary alveoli were not stained. In this
study, patients without and with CF had inverse staining pat-
terns of antigen in pulmonary tissues with these same antibod-
ies. For example, patients without CF had very little stained
antigen in the bronchial and bronchiolar epithelium yet a sig-
nificant amount of stained antigen in the alveolar epithelium.
In contrast, patients with CF had a significant amount of
stained antigen in the bronchial and bronchiolar epithelium yet
no stained antigen in the alveolar epithelium. Whether this
difference is a result of persistent respiratory bacterial infec-
tion or an abnormality associated with the CF phenotype that
increases the susceptibility of the respiratory tract to bacterial
infection is not yet known.
The origin of AP-like molecules is not yet known. In an
ovine model, AP molecules are synthesized in airway epithe-
lium, released into airway surface fluid, and disseminated
throughout the respiratory tract. Based on their known surfac-
tant-binding properties they could then become associated
with the alveolar epithelium. In patients without CF, AP-like
molecules may have been released from their sites of synthesis
and disseminated throughout the respiratory tract. In CF pa-
tients, there may be a block in release of the AP-like molecules
from their original sites of synthesis and hence an accumula-
tion in the respiratory tree but none in the distal alveoli. Per-
haps the abnormal airway fluid composition in CF contributes
to this lack of secretion or lack of trafficking throughout the
respiratory tract. Cytoplasmic staining of alveolar wall cells
could also contribute to the increase in staining found in the
alveoli. It could be that the difference in distribution of staining
is a result of production of two or more AP-like molecules: one
preferentially produced by epithelial cells and another pro-
duced by alveolar wall cells.
AP-like molecules may occur individually or as part of a
larger protein zymogen, and a number of observations are
consistent with this hypothesis. First, the amino acid sequence
of the ovine AP, H-DDDDDDD-OH, is similar to those of the
charge-neutralizing activation peptides of group I serine pro-
teases (e.g., human trypsinogen activation peptide, which has
the sequence H-VDDDDK-OH). Synthetic trypsinogen acti-
vation peptide and other similar fragments have antimicrobial
activity (4). Second, antibodies PAB96-1 and 1G9-1C2 recog-
nize several larger proteins (range, 25.7 to 53.7 kDa) in West-
ern blots of solubilized tracheal epithelial cells and lung ho-
mogenates (3). Third, a degenerate oligonucleotide sequence
of ovine AP and AP-like molecules used to probe a Southern
blot of human DNA identified strong hybridizing bands (all ,4
kb), also suggesting that AP is part of a much larger gene
product (data not shown). Finally, a number of AP-like sequences
have been found in other cellular and nuclear proteins. The
signal detected in nuclei may be based on multiple genes
known to be expressed in the nuclei, well characterized in hu-
mans, which encode products that contain AP-like peptide se-
quences including nucleophosmin, TFIID transcription factor,
and topoisomerase II. Although this may help explain the speci-
ficity of the epithelial cell nuclear staining, it does not explain the
differences in epithelial staining seen between the groups.
In summary, these observations form the foundation for
further work to isolate and characterize AP-like molecules
present in the human airway to assess their role in innate
pulmonary defense. Whether there is a genetic or physiologic
basis for differences in AP-like molecule concentrations in
patients with CF or whether changes in concentration affect
the susceptibility of the respiratory tract to pulmonary patho-
gens will have to be determined.
This research was supported by the Cystic Fibrosis Foundation
(BROGDE97Z0).
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